Search

CN-121987623-A - Application of indole in preparation of medicine for improving emotional symptoms of IBS patient

CN121987623ACN 121987623 ACN121987623 ACN 121987623ACN-121987623-A

Abstract

The application relates to application of indole in preparation of a medicament for improving emotional symptoms of patients with Irritable Bowel Syndrome (IBS). According to the application, the emotional symptoms of IBS patients can be caused by the reduction of the level of the intestinal indole for the first time, and the experiments prove that the anxiety and depression-like behaviors of IBS model animals can be obviously improved by supplementing exogenous indole.

Inventors

  • LI YADONG
  • Luo Yanjia
  • WANG TINGTING
  • ZHOU YING

Assignees

  • 上海市松江区中心医院（上海交通大学附属第一人民医院松江分院）

Dates

Publication Date
20260508
Application Date
20260326

Claims (10)

  1. 1. Use of indole for the preparation of a medicament for improving emotional symptoms in a patient suffering from Irritable Bowel Syndrome (IBS).
  2. 2. The use of claim 1, wherein the indole enhances AhR signaling in vDG of the IBS patient and the activity of vDG granulosa cells of the IBS patient by activating an indole-aromatic receptor (AhR) -ventral dentate gyrus (vDG) signaling pathway in the IBS patient to achieve an improvement in the emotional symptoms of the IBS patient.
  3. 3. The use according to claim 2, wherein the indole as ligand is bound to AhR in vDG of the IBS patient such that the AhR bound to the indole translocates into the nucleus, forms a heterodimer with an aromatic receptor nuclear translocation factor and binds to a dioxin response element to modulate downstream gene expression.
  4. 4. The use according to claim 1, wherein the emotional symptoms of the IBS patient are caused by a decrease in endogenous indole produced by the intestinal microbiota of the IBS patient via the tryptophan metabolic pathway.
  5. 5. The use according to claim 1, wherein the emotional symptoms of the IBS patient are caused by a decrease in tryptophan enzymes produced by the intestinal microbiota of the IBS patient.
  6. 6. The use according to claim 1, wherein the emotional symptoms of the IBS patient are caused by a decrease in the abundance of a. Saxifraga (ALISTIPES SHAHII, a. Shahii) in the intestinal microbiota of the IBS patient.
  7. 7. The use according to claim 1, characterized in that said indole is directly used as said medicament for improving the emotional symptoms of IBS patients.
  8. 8. The use according to claim 1, wherein the emotional symptoms of the IBS patient include anxiety and depression.
  9. 9. The use according to claim 1, wherein said indole is mixed with pharmaceutically acceptable excipients for the preparation of said medicament for improving the emotional symptoms of IBS patients.
  10. 10. The use according to claim 1, wherein the mode of administration of the medicament for ameliorating the emotional symptoms of a patient with IBS comprises oral administration or rectal administration.

Description

Application of indole in preparation of medicine for improving emotional symptoms of IBS patient Technical Field The application relates to the technical field of biological medicine, in particular to application of indole in preparation of a medicine for improving emotional symptoms of IBS patients. Background Irritable bowel syndrome (Irritable Bowel Syndrome, IBS) is a common functional disorder characterized by abdominal discomfort or pain associated with bowel habit disorders, but also associated with other gastrointestinal symptoms such as bloating. IBS patients often have more emotional symptoms such as anxiety and depression than healthy people, and these emotional symptoms affect the work, study and life of IBS patients, and reduce the quality of life, however, the underlying pathophysiological mechanism of IBS patients is not yet fully elucidated, and the existing treatment methods also often have limited effects or have more side effects. Thus, there is an urgent need for a strategy that can safely and effectively improve the emotional symptoms of Irritable Bowel Syndrome (IBS) patients to improve their quality of life. Disclosure of Invention The application aims to provide an application of indole in preparation of a medicine for improving emotional symptoms of IBS patients, so that a safe and effective potential medicine selection is provided for treating the emotional symptoms of the IBS patients, and the life quality of the IBS patients can be improved. The embodiment of the application provides application of indole in preparation of a medicine for improving emotional symptoms of IBS patients. Wherein the indole enhances AhR signaling in vDG of the IBS patient and vDG granulosa cells of the IBS patient by activating an indole-AhR-vDG signaling pathway in the IBS patient to achieve an improvement in emotional symptoms of the IBS patient. Wherein the indole as a ligand translocates the indole-bound AhR into the nucleus by binding to the AhR in vDG of the IBS patient, forms a heterodimer with an aromatic receptor nuclear translocation factor, and binds to a dioxin responsive element to modulate downstream gene expression. Wherein the emotional symptoms of the IBS patient are caused by a decrease in endogenous indole produced by the intestinal microbiota of the IBS patient via tryptophan metabolic pathways. Wherein the emotional symptoms of the IBS patient are caused by a decrease in tryptophan enzymes produced by the intestinal microbiota of the IBS patient. Wherein the emotional symptoms of the IBS patient are caused by a decrease in the abundance of ALISTIPES SHAHII in the intestinal microbiota of the IBS patient. Wherein the indole is directly used as the drug for improving the emotional symptoms of the IBS patient. Wherein the emotional symptoms of the IBS patient include anxiety and depression. Wherein, the indole is mixed with pharmaceutically acceptable auxiliary materials to prepare the medicine for improving the emotional symptoms of IBS patients. Wherein the administration of the drug for improving emotional symptoms of the IBS patient comprises oral administration or rectal administration. The application provides a new application of indole. According to the application, the emotional symptoms of IBS patients can be caused by the reduction of the level of the intestinal indole for the first time, and the experiments prove that the anxiety and depression-like behaviors of IBS model animals can be obviously improved by supplementing exogenous indole. Drawings The technical solution and other advantageous effects of the present application will be made apparent by the following detailed description of the specific embodiments of the present application with reference to the accompanying drawings. Fig. 1 shows the emotional symptoms of IBS patients and IBS model mice, regulated by intestinal microbiota, wherein fig. 1A shows sex, age and Body Mass Index (BMI) of 22 IBS patients and 35 healthy volunteers, fig. 1B and 1C show anxiety and depression assessment of 22 IBS patients and 35 healthy volunteers, scores were obtained using hamilton anxiety scale and hamilton depression scale, fig. 1D shows experimental design patterns for establishing IBS mice model, fig. 1E to fig. 1G show total distance and central area residence time percentage in OFT and immobility time in TST and FST for 16 control mice, fig. 1H shows emotional behavior test after Fecal Microbiota Transplantation (FMT), fig. 1I to fig. 1K show total distance and central area residence time percentage in TST and immobility time in FST for 12 sterile (GF) mice receiving healthy control group or FMT, fig. 1E to fig. 1K shows paired data of <0.01 to fig. 1 p, fig. 1 p to fig. 1C and 1 p to fig. 1 p. FIG. 2 is a graph of ALISTIPES SHAHII showing key microbiota responsible for the co-morbid symptoms of IBS, wherein FIG. 2A is a graph of linear discriminant analysis effect (LEfSe) showing a significant difference in the genus level